Anti-Infective Agents Market Research Report, Analysis and Forecast, till 2030

Evolving Demand Landscape in the Anti-Infective Agents Market 

According to Datavagyanik, the Anti-Infective Agents Market has witnessed significant transformation over recent years, with shifting pathogen profiles and emerging resistant strains driving advanced therapeutic research. For instance, the rise of antimicrobial resistance has generated an urgent need for novel classes of antibiotics, creating a vibrant innovation cycle within the Anti-Infective Agents Market. Healthcare systems across both developed and emerging economies are witnessing a substantial rise in hospital-acquired infections, prompting greater investment in targeted anti-infective therapies. The increasing volume of immunocompromised patients, such as those undergoing chemotherapy, further amplifies demand in the Anti-Infective Agents Market, supporting robust expansion trajectories. 

Expanding Indications Fuel Growth in the Anti-Infective Agents Market 

Datavagyanik identifies that new indications for anti-infective agents are fueling growth, broadening the applications of these therapeutics across numerous specialties. For example, the Anti-Infective Agents Market is seeing robust growth from the treatment of opportunistic infections in HIV-positive patients, which, according to global health data, affect nearly 38 million people worldwide. Furthermore, the application of advanced antifungal agents in critical care settings is accelerating, supported by a rise in invasive fungal infections among ventilated patients. This trend expands the clinical relevance of the Anti-Infective Agents Market, allowing players to explore innovative formulations and targeted combinations that address previously under-treated patient segments. 

Technological Advances Shaping the Anti-Infective Agents Market 

For instance, sustained-release delivery systems and nanoparticle-based formulations are transforming therapeutic outcomes by enhancing bioavailability and reducing side effects. According to Datavagyanik, technological integration has become a core strategy to maintain market competitiveness within the Anti-Infective Agents Market. Research on antimicrobial peptides and bacteriophage therapies demonstrates further disruptive potential, with early clinical trials reporting significant success in eradicating multi-drug resistant pathogens. Such breakthroughs are drawing the attention of investors seeking differentiated portfolios in the Anti-Infective Agents Market, accelerating capital inflows toward research partnerships and biopharma alliances. 

Anti-Infective Agents Market Size Gains Momentum with Global Population Trends 

Datavagyanik suggests that global population dynamics, particularly the aging demographic, have directly influenced the Anti-Infective Agents Market Size. For example, a rising elderly population — estimated to exceed 1.5 billion people by 2050 — is linked with higher susceptibility to infectious diseases due to immunosenescence. These individuals are more vulnerable to pneumonia, bloodstream infections, and urinary tract infections, propelling the Anti-Infective Agents Market forward. Moreover, the greater adoption of surgical interventions among elderly patients expands opportunities for perioperative anti-infective prophylaxis, underscoring the robust growth trajectory of the Anti-Infective Agents Market Size. 

Changing Regulatory Environments Impacting the Anti-Infective Agents Market 

For instance, Datavagyanik notes that streamlined regulatory approvals for priority anti-infective agents have positively reshaped market entry strategies. Initiatives such as the FDA’s Qualified Infectious Disease Product designation allow companies to expedite innovative therapies, reducing development timelines. This trend supports the Anti-Infective Agents Market by lowering barriers for niche product launches addressing highly resistant strains. Regulatory frameworks encouraging novel drug pathways have encouraged small and mid-sized biotech companies to invest in anti-infective pipelines, creating a dynamic and competitive ecosystem within the Anti-Infective Agents Market. 

Hospital-Acquired Infections Driving the Anti-Infective Agents Market 

The global burden of hospital-acquired infections, affecting roughly 7% of hospitalized patients in developed countries and up to 15% in developing countries, underscores critical opportunities in the Anti-Infective Agents Market. Datavagyanik indicates that multi-drug resistant organisms are a major driver for advanced combination therapies, as traditional monotherapies have become less effective. For example, the growing demand for combination cephalosporin-beta-lactamase inhibitors highlights an evidence-based approach to combating these infections. This pattern fuels innovation and enhances the clinical value proposition of the Anti-Infective Agents Market by expanding treatment choices for healthcare providers under mounting pressure to manage resistant infections. 

Pediatric Demand Transforming the Anti-Infective Agents Market 

Datavagyanik reports that pediatric patient needs are reshaping the Anti-Infective Agents Market, especially with the growing awareness around childhood respiratory and gastrointestinal infections. For instance, the WHO reports that pneumonia alone kills nearly 740,000 children under five every year, intensifying demand for safer and more effective anti-infective products for pediatric use. Companies are actively reformulating existing agents for pediatric-friendly administration routes, such as dispersible tablets and oral suspensions. This innovation extends the Anti-Infective Agents Market’s reach to a highly sensitive population, encouraging steady market expansion through specialized product pipelines. 

Immunocompromised Patient Base Sustaining the Anti-Infective Agents Market 

According to Datavagyanik, the Anti-Infective Agents Market benefits substantially from the growing number of immunocompromised individuals worldwide. For instance, cancer patients undergoing immunosuppressive chemotherapy or those with autoimmune diseases treated by biologics often experience heightened infection risks. Statistics suggest that 10–15% of oncology patients will develop severe infections during their treatment course, sustaining demand for next-generation broad-spectrum antibiotics. Likewise, antifungal prophylaxis has become routine in patients receiving stem cell transplants, reinforcing consistent demand within the Anti-Infective Agents Market. 

Pandemic Preparedness Bolstering the Anti-Infective Agents Market 

Datavagyanik highlights that pandemic preparedness initiatives since 2020 have permanently altered anti-infective supply chain models. For example, countries have established national stockpiles and diversified procurement channels for critical anti-infective classes, creating a more resilient Anti-Infective Agents Market. The COVID-19 pandemic revealed gaps in anti-infective readiness, leading to global funding for advanced antibiotic development pipelines. This preparedness has fostered a stronger manufacturing ecosystem, with contract manufacturing organizations expanding sterile injectables capacity to meet projected surges in demand during infectious disease outbreaks, reinforcing the structural growth of the Anti-Infective Agents Market. 

Increasing Investment Supports the Anti-Infective Agents Market 

The Anti-Infective Agents Market is witnessing substantial funding from both public and private sources. For instance, over USD 1.5 billion in global venture capital was invested in novel anti-infective research platforms in the past three years, as highlighted by Datavagyanik. Collaborations between biotech innovators and large pharmaceutical companies are accelerating product launches for innovative antimicrobials, antifungals, and antivirals. Such investments support the Anti-Infective Agents Market by reducing time-to-market and mitigating research risks, thereby strengthening the market’s ability to address fast-evolving pathogen landscapes. 

Growing Focus on Antifungal Treatments Within the Anti-Infective Agents Market 

Datavagyanik suggests that the Anti-Infective Agents Market is seeing a significant pivot toward antifungal therapeutics. Invasive fungal infections, such as aspergillosis and candidemia, are projected to rise at a CAGR of over 8% globally through 2030, creating a strong growth platform for antifungal product innovation. For instance, hospitals are implementing routine antifungal prophylaxis for transplant and leukemia patients, expanding the therapeutic window for newer azole and echinocandin agents. This demand for targeted antifungal therapies strengthens the long-term development pipeline in the Anti-Infective Agents Market, encouraging strategic investments in research and clinical validation. 

Regional Disparities Reshaping the Anti-Infective Agents Market 

The Anti-Infective Agents Market also reflects considerable regional disparities in infection rates and access to treatment. Datavagyanik points to sub-Saharan Africa and parts of Southeast Asia as regions with high infectious disease burdens yet underdeveloped healthcare infrastructures. For example, more than 400,000 malaria-related deaths occur annually in Africa alone, creating opportunities for anti-malarial product launches within the Anti-Infective Agents Market. Conversely, high-income markets are investing in advanced hospital-grade antibiotics and combination therapies to counter nosocomial pathogens, creating a dual-market dynamic that diversifies commercial opportunities in the Anti-Infective Agents Market. 

Sustainable Manufacturing Strategies Impacting the Anti-Infective Agents Market 

Sustainable production strategies are gaining traction within the Anti-Infective Agents Market, driven by global focus on greener manufacturing. Datavagyanik highlights that greener synthesis processes, including enzyme-catalyzed pathways and solvent reduction technologies, are gaining adoption across key manufacturers. For example, greener penicillin and cephalosporin production reduces environmental contamination while maintaining product quality, addressing both regulatory and societal demands. This shift reinforces a responsible and resilient supply chain, improving the long-term sustainability of the Anti-Infective Agents Market while meeting heightened global expectations for environmental stewardship. 

Future Outlook for the Anti-Infective Agents Market 

Datavagyanik projects that the Anti-Infective Agents Market will continue to advance through 2030, supported by next-generation therapies, innovative delivery platforms, and rising infection rates in both acute and chronic settings. For instance, global travel and climate change are likely to alter pathogen distribution patterns, introducing new challenges and opportunities for anti-infective developers. As pathogens evolve and global health risks become more complex, the Anti-Infective Agents Market is positioned to deliver high-value, precision-targeted therapies that redefine infection control worldwide. 

 

North America Dominates the Anti-Infective Agents Market 

According to Datavagyanik, North America remains the largest contributor to the Anti-Infective Agents Market, driven by advanced healthcare systems, high per capita spending, and a robust infection surveillance network. For instance, the region accounts for more than 35% of the global Anti-Infective Agents Market revenue, propelled by the widespread adoption of advanced antibiotics and combination antifungal therapies. Rising incidences of resistant pathogens in intensive care units, coupled with the expanding immunocompromised population, continue to fuel Anti-Infective Agents demand across North American hospitals. In addition, the presence of leading pharmaceutical innovators accelerates the introduction of pipeline products, strengthening the region’s leadership position in the Anti-Infective Agents Market. 

Europe’s Dynamic Anti-Infective Agents Market 

Datavagyanik highlights that Europe’s Anti-Infective Agents Market is shaped by sophisticated antimicrobial stewardship programs and rigorous hospital infection prevention frameworks. For example, countries like Germany, France, and the United Kingdom have prioritized hospital-acquired infection reduction, driving steady Anti-Infective Agents demand for both empiric and targeted therapy. The region has witnessed growing usage of combination beta-lactamase inhibitors to combat multi-drug resistant Enterobacterales, supporting a CAGR of nearly 5% in these segments through 2030. Furthermore, expanding home healthcare and outpatient care models in Europe are increasing the demand for oral anti-infective agents, contributing to a more diverse product mix in the Anti-Infective Agents Market. 

Asia Pacific Emerging as a High-Growth Anti-Infective Agents Market 

According to Datavagyanik, the Asia Pacific Anti-Infective Agents Market is experiencing a transformative growth phase, supported by rising population densities, expanding healthcare infrastructure, and increasing disease surveillance. For instance, Southeast Asia and India report some of the highest rates of antimicrobial resistance globally, pushing demand for next-generation antibiotics. National immunization programs and expanded insurance coverage have also opened access to life-saving anti-infective agents for lower-income populations. Datavagyanik projects that the Asia Pacific Anti-Infective Agents Market will deliver one of the strongest compound annual growth rates through 2030, with a significant portion of sales originating from China’s rapidly modernizing hospital sector. 

Latin America’s Contribution to the Anti-Infective Agents Market 

Datavagyanik observes that Latin America represents an evolving opportunity within the Anti-Infective Agents Market. For example, countries such as Brazil and Mexico are investing heavily in public health infrastructure and infection control protocols, supporting broader adoption of broad-spectrum antibiotics and antifungal products. Additionally, endemic infectious diseases including dengue, Chagas disease, and tuberculosis continue to sustain Anti-Infective Agents demand in the region. Improvements in regulatory oversight and supply chain networks are further stabilizing product availability, allowing the Anti-Infective Agents Market in Latin America to expand steadily despite economic volatility. 

Middle East and Africa Shaping the Anti-Infective Agents Market 

The Anti-Infective Agents Market in the Middle East and Africa is supported by high infection burdens, coupled with steadily improving healthcare delivery. Datavagyanik states that malaria, tuberculosis, and HIV continue to account for substantial morbidity and mortality in sub-Saharan Africa, driving consistent Anti-Infective Agents demand for first-line and second-line treatments. In the Gulf Cooperation Council states, rapidly expanding hospital investments and a growing medical tourism industry are boosting advanced antibiotic adoption, creating new prospects for premium brands in the Anti-Infective Agents Market. 

Segmentation by Drug Class Drives the Anti-Infective Agents Market 

Datavagyanik notes that segmentation by drug class is a critical pillar for the Anti-Infective Agents Market, with antibacterial agents maintaining a dominant share due to widespread use against common bacterial pathogens. For instance, cephalosporins, macrolides, and carbapenems remain highly utilized segments because of their proven effectiveness against resistant Gram-negative bacteria. The antifungal class is projected to grow at over 7% CAGR, driven by invasive fungal infections among immunosuppressed patients. The antiviral segment, particularly focused on hepatitis and influenza, is expanding due to greater public health vaccination gaps and evolving virus strains, strengthening its place within the Anti-Infective Agents Market. 

Segmentation by Route of Administration in the Anti-Infective Agents Market 

The Anti-Infective Agents Market also segments by route of administration, where intravenous anti-infective agents dominate hospital-based therapy due to their rapid action in severe infections. Datavagyanik highlights that the injectable segment alone represents over 55% of the total Anti-Infective Agents Market, supported by critical care procedures and perioperative prophylaxis. On the other hand, oral formulations remain crucial in outpatient and community settings for diseases such as urinary tract infections and community-acquired pneumonia. For example, dispersible tablet formulations for pediatric patients are seeing increasing demand in developing countries, providing accessible and convenient solutions for broader Anti-Infective Agents Market coverage. 

Segmentation by Distribution Channel Expands the Anti-Infective Agents Market 

Datavagyanik explains that hospital pharmacies continue to be the primary distribution channel for the Anti-Infective Agents Market due to the high share of acute, life-threatening infections treated within hospitals. However, retail pharmacies are steadily growing in relevance as awareness increases for early-stage infection management and self-administration therapies. For example, emerging markets with high antibiotic misuse issues are promoting strict pharmacist-led dispensing models to maintain control, stabilizing the Anti-Infective Agents Market by reducing inappropriate usage. Additionally, online pharmacies and e-health channels are becoming more significant in distributing anti-infective products, driven by telehealth adoption and changing consumer behaviors. 

Anti-Infective Agents Market Pricing Trends Shaped by Generic Competition 

Datavagyanik points out that the Anti-Infective Agents Market has experienced significant pricing pressure in recent years due to the proliferation of generics. For instance, generic penetration in cephalosporins and macrolides exceeds 70% in mature markets, sharply reducing the average selling price for these classes. While this benefits accessibility, it has created challenges for originator companies seeking to recapture R&D investments. In response, premium pricing strategies for advanced combination products, supported by clinical differentiation, are becoming critical to maintaining sustainable revenue within the Anti-Infective Agents Market. 

Premium Pricing Opportunities in the Anti-Infective Agents Market 

Datavagyanik indicates that premium pricing opportunities exist for next-generation antibiotics targeting carbapenem-resistant organisms, where treatment alternatives are extremely limited. For example, combination ceftazidime-avibactam therapies have commanded prices 2–3 times higher than older antibiotics, reflecting their life-saving profile. Similarly, advanced antifungal agents for resistant Candida infections justify higher price points due to their superior safety and efficacy profiles. These dynamics encourage continuous innovation and help preserve a profitable premium segment within the Anti-Infective Agents Market, balancing against the otherwise high levels of generic competition. 

Regional Price Variation Influencing the Anti-Infective Agents Market 

Price variations across regions play a crucial role in shaping the Anti-Infective Agents Market. For instance, North America and Western Europe maintain higher reimbursement rates for innovative anti-infective agents, allowing better price realization. Conversely, emerging economies often prioritize essential medicines procurement through public tenders, exerting downward price pressure. Datavagyanik observes that price disparities of up to 60% between high-income and low-income markets influence portfolio strategies, prompting manufacturers to adapt tiered pricing models to protect Anti-Infective Agents demand while ensuring product reach. 

Access and Affordability Challenges in the Anti-Infective Agents Market 

Datavagyanik emphasizes that affordability continues to be a core challenge within the Anti-Infective Agents Market, particularly across low-income countries with fragile health systems. For instance, essential antibiotics remain unaffordable for nearly 50% of low-income populations, despite being on national essential medicines lists. This situation has led to international collaborations with non-governmental organizations and multilateral agencies to subsidize anti-infective procurement and distribution, preserving consistent Anti-Infective Agents demand in vulnerable populations. These access partnerships are becoming critical to sustaining equitable growth in the Anti-Infective Agents Market globally. 

Supply Chain Resilience Boosts the Anti-Infective Agents Market 

Supply chain continuity has become a priority since recent pandemics exposed vulnerabilities. According to Datavagyanik, manufacturers in the Anti-Infective Agents Market are diversifying their active pharmaceutical ingredient (API) sourcing and enhancing domestic production capacity to counter potential geopolitical disruptions. For instance, several companies have established secondary manufacturing hubs outside China and India, ensuring a more resilient product flow to key markets. This strategic transformation supports long-term Anti-Infective Agents demand and stabilizes prices by minimizing shortages that otherwise drive emergency procurement at inflated costs. 

Strategic Partnerships Reshaping the Anti-Infective Agents Market 

Datavagyanik reports that strategic partnerships between multinational companies and local producers have intensified across the Anti-Infective Agents Market. For example, technology transfer deals for antibiotic manufacturing allow local facilities to produce advanced formulations while maintaining global quality standards. Such collaborations lower production costs, expand product reach, and strengthen distribution networks, fostering a healthier price environment and improving Anti-Infective Agents demand in emerging regions. Additionally, these alliances help accelerate local regulatory approvals, speeding up market entry and bolstering competitiveness. 

Future Price Trends in the Anti-Infective Agents Market 

The pricing outlook for the Anti-Infective Agents Market is expected to stabilize over the next five years, according to Datavagyanik. For example, as resistance patterns become clearer, governments are investing in antibiotic stewardship programs to curb misuse and encourage premium product uptake. This will sustain rational pricing and protect innovation pipelines, while generics will continue to dominate routine infection therapy. The balance between advanced anti-infective products and essential generics will anchor price stabilization across the Anti-Infective Agents Market while supporting predictable Anti-Infective Agents demand. 

Competitive Segmentation Strengthening the Anti-Infective Agents Market 

Datavagyanik highlights that competitive segmentation within the Anti-Infective Agents Market is evolving, with both multinational giants and niche biotechs securing strong positions. For example, large companies are dominating hospital-based intravenous antibiotic markets with broad portfolios, while smaller players focus on highly differentiated antifungal or antiviral agents. This diversity enriches the Anti-Infective Agents Market, ensuring no single player monopolizes the innovation landscape. In turn, this competitive environment supports continuous investment in R&D and a healthy pipeline of new molecules, meeting the growing Anti-Infective Agents demand across diverse geographies. 

Digital Healthcare Transforming the Anti-Infective Agents Market 

Datavagyanik points to the rise of digital healthcare as a transformative trend in the Anti-Infective Agents Market. For instance, remote diagnostics and telehealth solutions are expanding early identification of infections, supporting faster initiation of anti-infective therapies. Digital prescribing platforms are also improving compliance and adherence, particularly in chronic infections. These innovations are improving therapeutic outcomes, driving sustained Anti-Infective Agents demand, and facilitating better antimicrobial stewardship — all crucial for containing resistance and maintaining long-term Anti-Infective Agents Market growth. 

Outlook for Segmentation and Price Dynamics in the Anti-Infective Agents Market 

Datavagyanik concludes that segmentation and pricing strategies will continue to define the next growth cycle for the Anti-Infective Agents Market. For instance, combination therapies, pediatric-friendly formulations, and niche antifungal or antiviral treatments will secure premium positions, while older, commoditized antibiotics will maintain volume-based competitive pricing. Regional disparities and emerging market demands will require pricing flexibility and supply chain optimization. Collectively, these factors will shape a balanced and sustainable Anti-Infective Agents Market, preserving access and encouraging continuous innovation to meet rising Anti-Infective Agents demand worldwide. 

 

Leading Companies in the Anti-Infective Agents Market 

Datavagyanik highlights that a select group of multinational players dominate the Anti-Infective Agents Market, leveraging advanced R&D, extensive distribution capabilities, and strategic partnerships to consolidate their positions. These major contributors include Pfizer, Merck, GlaxoSmithKline, Novartis, Roche, Astellas Pharma, Gilead Sciences, and Teva Pharmaceuticals. Their combined presence accounts for a significant share of global revenues in the Anti-Infective Agents Market, setting industry benchmarks for innovation and access. 

Pfizer holds an estimated 12 percent share of the Anti-Infective Agents Market, supported by strong sales of products such as meropenem-vaborbactam, a powerful beta-lactamase inhibitor combination therapy used to treat resistant Gram-negative infections. Its broad hospital-focused portfolio, alongside emerging assets in next-generation antibiotics, reinforces Pfizer’s leadership in the Anti-Infective Agents Market. 

Merck commands close to 10 percent share, benefiting from its robust antifungal and antiviral offerings. Caspofungin, an echinocandin used in invasive candidiasis, and letermovir for cytomegalovirus prophylaxis are among its most notable products driving consistent Anti-Infective Agents demand across critical care and transplant segments. 

GlaxoSmithKline holds around 8 percent of the Anti-Infective Agents Market, with strong positions in antiretroviral and advanced cephalosporin therapies. Its products such as dolutegravir for HIV and ceftaroline for MRSA infections are widely adopted in both developed and emerging healthcare systems. 

Novartis has captured roughly 7 percent of the global Anti-Infective Agents Market, leveraging a targeted strategy in antimicrobial peptides and novel anti-bacterial molecules aimed at overcoming resistance challenges. Its research collaborations and late-stage development programs are expected to further expand its share in hospital and community-based anti-infective treatment. 

Roche maintains approximately 5 percent share, supported by a unique combination of antiviral therapeutics and a robust diagnostics division. Its approach to linking infection diagnosis with immediate anti-infective intervention positions Roche strongly in the integrated care model within the Anti-Infective Agents Market. 

Astellas Pharma focuses heavily on antifungal agents, holding a market share of about 4 percent through products such as micafungin, widely used in high-risk immunocompromised patients. Its continued investments in novel azole derivatives are set to secure higher growth rates in the coming years. 

Gilead Sciences sustains close to 4 percent of the Anti-Infective Agents Market, with a highly regarded antiviral franchise including oseltamivir for influenza and innovative hepatitis treatments. Its strategic focus on addressing chronic viral infections provides Gilead with resilience against cyclical changes in antibacterial drug consumption. 

Teva Pharmaceuticals, primarily known for generics, has established a 3 percent foothold by providing affordable and high-quality versions of commonly used antibiotics, expanding Anti-Infective Agents demand in price-sensitive regions such as Latin America and Southeast Asia. 

 

Anti-Infective Agents Market Product Portfolios 

Key players in the Anti-Infective Agents Market differentiate themselves with specialized product portfolios. For instance, Pfizer’s meropenem-vaborbactam has become a reference therapy for resistant Gram-negative infections. Merck’s caspofungin is a standard of care for invasive fungal infections in intensive care settings. 

GlaxoSmithKline’s ceftaroline provides broad-spectrum coverage for hospital-acquired pneumonia and resistant skin infections. Novartis is progressing with next-generation antimicrobial peptides, while Roche maintains a solid antiviral suite with a focus on HIV and hepatitis therapies. 

Astellas is investing in expanding beyond micafungin to newer antifungal mechanisms, and Gilead remains committed to advancing antiviral solutions to tackle shifting viral epidemiology. Teva continues to reinforce its place in the Anti-Infective Agents Market by meeting essential drug demands through its wide generic antibiotic portfolio. 

 

Market Shares by Therapy Area 

Datavagyanik observes that antibacterial agents account for approximately 65 percent of the Anti-Infective Agents Market, driven by high demand for hospital-grade intravenous antibiotics. Antifungal treatments represent about 20 percent, supported by growth in immunocompromised patient populations requiring preventive and curative antifungal therapies. 

Antiviral agents comprise nearly 12 percent of the market, largely supported by chronic viral diseases such as HIV, hepatitis, and seasonal influenza. Other smaller categories, including antiparasitics, contribute the remaining 3 percent, often focused on tropical disease burdens in lower-income regions. 

 

Recent Developments and Strategic Updates 

April 2025 witnessed Pfizer reporting positive results from a Phase III study of a novel beta-lactamase inhibitor combination designed to fight carbapenem-resistant pathogens. This development strengthens its product pipeline and positions Pfizer for additional market share growth. 

In May 2025, Merck secured an expanded indication for caspofungin, allowing its use in treating invasive aspergillosis. This approval widens its application in critical care and strengthens Merck’s leadership in the antifungal sector of the Anti-Infective Agents Market. 

June 2025 saw GlaxoSmithKline entering a partnership with a South Korean biotechnology firm to co-develop a new oral antiviral aimed at combating emerging respiratory viral infections. This agreement targets a launch window around 2028 and reflects the strategy to expand antiviral therapy capabilities. 

Also in June 2025, Astellas announced the acquisition of an innovative antifungal startup specializing in novel azole molecules. This acquisition is aimed at reinforcing Astellas’s position in invasive fungal infection management and securing premium antifungal market share. 

By late June 2025, a global initiative with broad industry participation was launched to subsidize essential antibiotics for low-income countries, helping bridge access gaps in underfunded health systems. Pfizer, Merck, and Teva are among the industry participants actively supporting this effort, which is expected to improve Anti-Infective Agents demand across vulnerable geographies. 

 

Key Insights that the Anti-Infective Agents Market analysis report presents are:

• Anti-Infective Agents Market revenue and demand by countries
• Break-down of the Anti-Infective Agents Market in terms of application areas, target customers, and other potential market segments
• Areas that are relatively more potential and are faster growing
• Anti-Infective Agents Market competitive scenario, market share analysis
• Anti-Infective Agents Market business opportunity analysis

Global and Country-Wise Anti-Infective Agents Market Statistics

• Global and Country-Wise Anti-Infective Agents Market Size ($Million) and Forecast, till 2030
• Global and Country-Wise Anti-Infective Agents Market Trend Analysis
• Global and Country-Wise Anti-Infective Agents Market Business Opportunity Assessment